Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells $92,046.00 in Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Free Report) insider Behrad Derakhshan sold 4,600 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $20.01, for a total value of $92,046.00. Following the completion of the sale, the insider now directly owns 7,020 shares of the company’s stock, valued at $140,470.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Edgewise Therapeutics Trading Down 1.7 %

EWTX stock opened at $19.47 on Monday. The company has a market capitalization of $1.24 billion, a P/E ratio of -13.71 and a beta of 0.16. Edgewise Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $20.69. The business has a 50 day simple moving average of $11.78 and a 200-day simple moving average of $8.39.

Edgewise Therapeutics (NASDAQ:EWTXGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Research analysts predict that Edgewise Therapeutics, Inc. will post -1.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wedbush decreased their price objective on Edgewise Therapeutics from $27.00 to $23.00 and set an “outperform” rating for the company in a report on Friday, November 10th.

View Our Latest Analysis on EWTX

Institutional Investors Weigh In On Edgewise Therapeutics

Several large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its position in Edgewise Therapeutics by 23.4% in the first quarter. JPMorgan Chase & Co. now owns 27,166 shares of the company’s stock worth $263,000 after acquiring an additional 5,156 shares in the last quarter. MetLife Investment Management LLC raised its position in Edgewise Therapeutics by 55.4% in the first quarter. MetLife Investment Management LLC now owns 23,355 shares of the company’s stock worth $227,000 after acquiring an additional 8,328 shares in the last quarter. Rhumbline Advisers raised its position in Edgewise Therapeutics by 20.8% in the first quarter. Rhumbline Advisers now owns 36,861 shares of the company’s stock worth $358,000 after acquiring an additional 6,350 shares in the last quarter. BlackRock Inc. raised its position in Edgewise Therapeutics by 0.4% in the first quarter. BlackRock Inc. now owns 2,055,160 shares of the company’s stock worth $19,934,000 after acquiring an additional 7,557 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Edgewise Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 1,211,093 shares of the company’s stock worth $11,748,000 after acquiring an additional 11,693 shares in the last quarter.

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

See Also

Insider Buying and Selling by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.